Actively Recruiting
CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes
Led by Vida Recoletas Sevilla · Updated on 2025-01-23
160
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
V
Vida Recoletas Sevilla
Lead Sponsor
U
University of Seville
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the levels of the CENP-V protein in human oocytes to understand its role as a potential diagnostic marker for oocyte damage related to aging and the freezing process called vitrification. The study focuses on women with advanced maternal age (AMA) and compares them to younger control patients. The research addresses a concern that aging and freezing may reduce oocyte quality, affecting fertility and survival rates after thawing. The study involves analyzing immature oocytes that would otherwise be discarded from patients with AMA and control patients, as well as oocytes subjected to vitrification and thawing. Patients are divided into groups by age and fertility status, including those undergoing ovarian stimulation and oocyte collection. Only immature or donated mature oocytes not used for treatment are included in the analysis. Participants will have their oocytes collected and assessed within two days from enrollment to retrieval. The study measures the levels and distribution of CENP-V in these oocytes and tracks the survival rate of oocyte cohorts after thawing. This observational study does not involve treatment but focuses on laboratory analysis to identify markers of oocyte damage, which could inform future fertility evaluations.
CONDITIONS
Brief Title
CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 36 to 45 years with advanced maternal age as the main cause of infertility undergoing controlled ovarian stimulation
- Patients aged 18 to 45 years who have undergone oocyte vitrification and thawing, including subgroups of advanced maternal age (36-45 years) and non-advanced maternal age (18-35 years)
- Control patients and donors aged 18 to 35 years with normal fertility undergoing ovarian stimulation and oocyte collection
You will not qualify if you...
- Patients with conditions affecting oocyte quality such as polycystic ovary syndrome, premature ovarian insufficiency, endometriosis, or cancer
- Patients or donors whose oocytes were cryopreserved using slow freezing techniques rather than vitrification
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 days
Participants undergo ovarian stimulation and oocyte retrieval, during which immature or donated mature oocytes are collected for analysis.
1 to 2 visits depending on ovarian stimulation and retrieval schedule
Duration - Varies depending on sample processing
Collected oocytes are analyzed fresh and after vitrification-thawing to measure CENP-V protein levels as a diagnostic marker of damage.
No participant visits; analysis performed on collected samples
Trial Site Locations
Total: 1 location
1
Vida Recoletas Sevilla S.L.
Seville, SEVILLA, Spain, 41009
Actively Recruiting
Research Team
E
ESTHER SANTAMARÍA LÓPEZ
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here